Shandong Wohua Pharmaceutical (SZ:002107) 2 1 Shi Ji Jing Ji Bao Dao·2025-11-11 07:05Core Viewpoint - The divorce property dispute between Zhao Bingxian and Lu Juan, involving significant assets and control over Wohuamedicine, has concluded with a court ruling that splits their shares in the controlling entity, Zhongzheng Wanrong Investment Group, equally, resulting in Wohuamedicine having no actual controller [2][10][14]. Group 1: Legal Proceedings and Outcomes - The court's second-instance ruling maintains the first-instance decision, mandating an equal division of shares in Zhongzheng Wanrong, which holds a 50.27% stake in Wohuamedicine [2][10]. - Zhao Bingxian previously held 80% of Zhongzheng Wanrong, while Lu Juan held 20%; post-division, both will hold 50% [2][10]. - Lu Juan expressed that the equal shareholding will prevent dominance by a single major shareholder and promote the company's healthy development [3][14]. Group 2: Company Background and Performance - Wohuamedicine, established in 2002 and listed in 2007, specializes in the research, production, and sales of natural plant-based cardiovascular traditional Chinese medicine [11]. - The company's core products include Wohuaxin Keshupian and other proprietary medications, which are crucial for its revenue and profit [11]. - Recent years have seen declining performance, with net profit decreasing for four consecutive years from 2021 to 2024, largely due to price reductions and high marketing costs [12]. Group 3: Financial Data and Market Response - As of November 10, 2025, Wohuamedicine's total market value was approximately 3.648 billion yuan, with Lu Juan's share from the division valued at about 547 million yuan [3]. - Despite the ongoing legal issues, the company's stock price remained stable following the announcement of the court ruling, with slight increases noted in the days after [14]. - In the first three quarters of 2025, Wohuamedicine reported a revenue of 625 million yuan, marking an 8.31% year-on-year increase, and a net profit of approximately 63.995 million yuan, reflecting a significant growth of 179.34% [12].